Subsequent results from the AENEAS study showed that almonertinib also had great efficacy in the first-line treatment of advanced or metastatic NSCLC patients with EGFR exon 19 deletion or exon 21 (L858R) mutation (13). Here, EGFR is linked to non-small cell lung carcinoma.